|Home | About | Journals | Submit | Contact Us | Français|
Conceived and designed the experiments: UM AKD AA BG SKS. Performed the experiments: UM TA RR GDL. Analyzed the data: UM AKD AA BG SKS. Wrote the paper: UM AKD AA BG SKS.
Baicalein, a bioflavone present in the dry roots of Scutellaria baicalensis Georgi, is known to reduce eotaxin production in human fibroblasts. However, there are no reports of its anti-asthma activity or its effect on airway injury.
In a standard experimental asthma model, male Balb/c mice that were sensitized with ovalbumin (OVA), treated with baicalein (10 mg/kg, ip) or a vehicle control, either during (preventive use) or after OVA challenge (therapeutic use). In an alternate model, baicalein was administered to male Balb/c mice which were given either IL-4 or IL-13 intranasally. Features of asthma were determined by estimating airway hyperresponsiveness (AHR), histopathological changes and biochemical assays of key inflammatory molecules. Airway injury was determined with apoptotic assays, transmission electron microscopy and assessing key mitochondrial functions. Baicalein treatment reduced AHR and inflammation in both experimental models. TGF-β1, sub-epithelial fibrosis and goblet cell metaplasia, were also reduced. Furthermore, baicalein treatment significantly reduced 12/15-LOX activity, features of mitochondrial dysfunctions, and apoptosis of bronchial epithelia.
Our findings demonstrate that baicalein can attenuate important features of asthma, possibly through the reduction of airway injury and restoration of mitochondrial function.
Asthma is associated with recruitment of various inflammatory cells such as eosinophils and lymphocytes to the airway. These cells release various reactive free radicals to create an oxidative microenvironment in the airway , which injures structural cells of airway such as bronchial epithelial cells. Repeated allergic inflammation leads to irreversible epithelial injury and causes the detachment of ciliated bronchial epithelial cells from the basement membrane. In support of this view, epithelial clumps have been found in sputum (creola bodies) and bronchoalveolar lavage (BAL) of asthmatic patients . While inflammatory cells such as Th2 lymphocytes, eosinophils, and mast cells have historically occupied center stage in asthma research, recent reports have highlighted the critical role of epithelial stress in deciding the immune responses within the lung –. Epithelial injury is now considered to be one of the primary pathogenic mechanisms for the development of various features of allergic asthma . Interestingly, restoring mitochondrial function of airway epithelia is sufficient to reduce acute lung injury, indicating the efficiency of mitochondria in maintaining epithelial homeostasis and thus the viability of the lung . We and others have previously demonstrated the association of mitochondrial structural changes in bronchial epithelia with asthma, and the pro-inflammatory effects of mitochondrial dysfunction –. Thus, it is of interest to explore therapeutic agents that can restore mitochondrial function as a means of reducing the deleterious effects of airway epithelial injury.
Baicalein (5, 6, 7-trihydroxy-2-phenyl-4H-1-benzopyran-4-one), a bioflavone component present in the dry roots of Scutellaria baicalensis Georgi, has been described in the Chinese Pharmacopoeia as a drug. It possesses a wide range of biological activities such as antiviral, antioxidant, anti-inflammatory, antithrombotic, and anticancer effects . It has been shown to inhibit the activity of the 15-lipoxygenase (15-LOX), which has been implicated in mitochondrial degradation in reticulocytes. It also reduces eotaxin production in cultured human fibroblasts stimulated by the combination of interleukin-4 and TNF-α . Though it has been suggested that baicalein may have anti-allergic effects based on in-vitro studies , this has not been confirmed in vivo. Importantly, baicalein reduces neuronal injury , , and inhibits retinal epithelial apoptosis induced by hydrogen peroxide . In light of this, we hypothesized that baicalein may have anti-asthma activity.
To determine the effects of baicalein (BAIC) on asthma features, male Balb/c mice were sensitized and challenged with OVA and treated with different concentrations of BAIC from the onset of allergen challenge (Fig. 1A). To determine the effect of baicalein on AHR, single chamber plethysmography was performed (see Materials and Methods). The concentration of methacholine (MCh) at which mice had developed 200% increase in enhanced pause (Penh) from the baseline values (MCh PC200 Penh) was determined. Penh is an index of airway hyperresponsiveness and it is directly proportional to airway obstruction. At the end of allergen challenge, the OVA/OVA/VEH group (allergic control mice) exhibited the development of AHR as those mice developed airway obstruction even at the low doses of methacholine than the SHAM/PBS/VEH (normal control mice). In this model, BAIC reduced AHR in a dose dependent manner and the optimal effective dose was 10 mg/kg (Fig. 1B). Therefore subsequent experiments were performed using the 10 mg/kg dose, unless otherwise indicated. For confirmation, we again estimated AHR, this time through invasive airway mechanics, which are considered more reliable. This confirmed that BAIC (10 mg/kg) treatment to OVA induced mice was associated with a significant reduction in AHR (Fig. 1C).
To determine the effect of BAIC on airway inflammation, histopathological analysis was performed on sections stained with Haematoxylin and Eosin stained lung sections. As shown in Fig. 1D, the OVA/OVA/VEH mice developed perivascular and peribronchial infiltration of inflammatory cells including eosinophils, compared to the control (SHAM/PBS/VEH) mice. In contrast, the OVA/OVA/BAIC mice showed a significant reduction in inflammation both around the vessel and bronchi. This was confirmed by objective inflammation scoring (Table 1).
Since eotaxin plays a significant role in the migration of eosinophils to the airway, we measured its levels in lung homogenates. As shown in Table 1, eotaxin levels were significantly higher in the OVA/OVA/VEH mice compared to the SHAM/PBS/VEH mice. BAIC treatment reduced the eotaxin levels significantly compared to the OVA/OVA/VEH mice. The increase in eotaxin levels was associated with an increase in the recruitment of eosinophils in the airway in the OVA/OVA/VEH mice (Fig. 1E) and baicalein treatment reduced airway eosinophilia.
To determine the effects of BAIC on Th2 cytokines and IgE, we measured the levels of IL-4 and IL-13 in lung tissue and OVA specific IgE in sera. As shown in Table 1, the levels of IL-4, IL-13 and OVA specific IgE were increased in the OVA/OVA/VEH mice compared to the SHAM/PBS/VEH mice. BAIC treatment was associated with a significant reduction of both the cytokines and also OVA specific IgE (Table 1). In addition, BAIC treatment significantly increased OVA specific IgG2a (Table 1). Since there was an increase in IgG2a, we measured IFN-γ levels in lung tissue. As shown in Table 1, IFN-γ levels were decreased in the OVA/OVA/VEH mice compared to the SHAM/PBS/VEH mice. However, BAIC treatment to allergic mice was associated with a significant increase in IFN-γ levels (Table 1).
Since baicalein appears to restore the balance the altered Th1/Th2 response in the allergically inflamed lungs, we tested the effect of baicalein on Toll-Like receptor proteins such as TLR-2 and TLR-4, as it is known that TLR-2 and TLR-4 skew the Th responses towards Th2 and Th1 respectively . As shown in Table 1, both TLR-2 and TLR-4 were found to be increased in the OVA/OVA/VEH mice compared to the SHAM/PBS/VEH mice. BAIC treatment to allergic mice was associated with a significant decrease in TLR-2 levels, but TLR-4 levels were unchanged (Table 1).
To determine the effect of BAIC on airway remodeling changes, we determined the effect of BAIC on goblet cell metaplasia and sub-epithelial fibrosis. To determine the effect of BAIC on goblet metaplasia, we performed periodic acid-Schiff staining on the lung sections. As shown in Fig. 2A, the OVA/OVA/VEH mice displayed the increased goblet cell metaplasia and BAIC treatment reduced it, which was confirmed by morphometric analysis.
As shown in Fig. 2B, dense accumulation of collagen was found in sub-epithelial regions of bronchi and also around vascular regions in allergic control mice compared to normal control mice. Interestingly, BAIC treatment had significantly reduced the collagen deposition in the bronchovascular regions (Fig. 2B). This was further confirmed by morphometry. Since TGF-β1 is important in the development of sub-epithelial fibrosis, we determined the effect of BAIC on the levels and expression of TGF-β1. As shown in Fig. 2C, the OVA/OVA/VEH mice showed a significant expression of TGF-β1 especially in the subepithelial mesenchymal regions and increased levels in lung cytosol relative to the SHAM/PBS/VEH mice (Fig. 2C, iv). Interestingly, BAIC treatment resulted in the reduction in the expression and levels of TGF- β1 in lung (Fig. 2C, i–iv).
Since baicalein showed anti-asthma effect in the preventive model, we wanted to test its efficacy in a therapeutic model. To determine the therapeutic effect of baicalein in asthma, it was administered to the mice after the development of asthma symptoms (Fig. 1A). Since allergen exposure is likely to continue during asthma therapy of human subjects, OVA challenges were continued during the BAIC treatment, until day 32 (Fig. 1A). The OVA-sensitized and -challenged mice showed asthma features such as MCh induced AHR and airway inflammation after 6 days OVA challenge (data not shown). BAIC treatment was therefore started after 6 days of OVA challenge, but with the continuation of OVA challenge. In this therapeutic model, BAIC treatment reduced AHR as well as the infiltration of inflammatory cells in the bronchovascular regions and inflammation score (Fig. 3A, B).
To further confirm the anti-asthma activities of BAIC, it was administered to naïve mice, which were given intranasal IL-13 or IL-4 (Fig. 4A). As expected, administration of IL-13 led to a significant increase in AHR and infiltration of inflammatory cells in the bronchovascular regions, with corresponding increase in inflammation score (Fig. 4B, C). However, BAIC administration to IL-13 treated mice led to a significant reduction in both AHR and airway inflammation (Fig. 4B, C). In addition, mice administered with IL-4 also showed an increase in AHR and airway inflammation, which was attenuated by BAIC (Fig. 4D, E).
Baicalein inhibits 15-LOX activity potently but not specifically , . 15-LOX metabolites such as 13-S-HODE and 9-S-HODE are generated in high concentrations during mitochondrial degradation in the reticulocytes during the process of reticulocyte maturation , . 15-LOX is also found to be increased in bronchial epithelia in human asthmatic conditions and mitochondrial dysfunction seems to be crucial in the pathogenesis of various respiratory diseases including asthma . 15-LOX preferentially utilizes linoleic acid (LA) to produce 9 and 13-(S)-hydroxyoctadecaenoic acids (HODEs) and also minimally utilizes arachidonic acid (AA) to produce 12-(S)-hydroxyeicosatetraenoic acids (HETE) . In this context, we determined the effect of baicalein on mitochondrial dysfunction and airway epithelial injury. We first measured the levels of 13-S-HODE and 9-S-HODE, which are the 15-LOX metabolites. As shown in Fig. 5A & B, the OVA/OVA/VEH mice had an increase in the levels of 13-S-HODE and 9-S-HODE compared to the SHAM/PBS/VEH mice. However, BAIC treatment significantly reduced the levels of both metabolites (Fig. 5 A, B).
To determine the effect of baicalein on mitochondrial function in the experimental asthma model, we measured cytochrome c oxidase activity and normalized by respective citrate synthase activity in lung mitochondria. The results indicated that the normalized cytochrome c oxidase activity was decreased in the OVA/OVA/VEH mice compared to the SHAM/PBS/VEH (Fig. 5C). Also, there was a reduction in complex I activity in lung mitochondria of the OVA/OVA/VEH mice. In addition, subunit III was found to be predominantly expressed in bronchi of the SHAM/PBS/VEH mice, and was found to be significantly decreased in the OVA/OVA/VEH mice (Fig. 5D). The high expression of subunit III in bronchial epithelia may relate to vulnerability to inflammatory insults . Interestingly, BAIC significantly restored the activities of cytochrome c oxidase and complex I with the restoration of the expression of subunit III of cytochrome c oxidase (Fig. 5C–E).
As BAIC restored the reduction in cytochrome c oxidase activity and complex I activity in allergic control mice, we further analyzed the cytochrome c levels and caspase 3 activities in lung cytosol. As shown in Fig. 6A, the OVA/OVA/VEH mice showed increased levels of cytochrome c in the lung cytosol compared to the SHAM/PBS/VEH mice. However, the OVA/OVA/BAIC mice showed a significant reduction of cytochrome c in the cytosol (Fig. 6A). In addition, the OVA/OVA/VEH mice also had increased activities of caspase 3 and caspase 12, treatment with BAIC was able to decrease their enzymatic activities. (Fig. 6B, C).
We measured oxidative stress as a means of analyzing mitochondrial dysfunction using 8-isoprostane, a reliable marker of lipid peroxidation. As shown in Fig. 6D, 8-isoprostane was found to be significantly increased in the OVA/OVA/VEH mice compared to the SHAM/PBS/VEH mice, and was significantly reduced by BAIC.
Since increased cytochrome c stimulated the intrinsic apoptotic pathway, we measured the levels of 8-hydroxy-2′-deoxyguanosine (8-OHdG), a marker for the oxidative DNA damage, in BAL fluid supernatants. We found an increase in 8-OHdG levels in the OVA/OVA/VEH mice compared to the SHAM/PBS/VEH mice, and was reduced by BAIC treatment (Fig. 6E). Furthermore, we performed TUNEL apoptosis assay in lung sections to determine the apoptotic index in this organ. As shown in Fig. 6F & G, the OVA/OVA/VEH mice showed increased apoptosis, especially in bronchial epithelial cells. However, BAIC treatment showed a significant reduction in DNA fragmentation (Fig. 6F & G).
To determine the effect of BAIC on morphological changes of the mitochondria in bronchial epithelium, we performed transmission electron microscopy. As shown in Fig. 6H, the OVA/OVA/VEH mice showed maximal mitochondrial damage in the form of loss or disruption of cristae, swelling and thinned outer membrane. However, BAIC treatment significantly restored the mitochondria to its normal architecture (Fig. 6H).
To further determine the effect of baicalein on airway injury, we determined the features of mitochondrial dysfunction and TUNEL apoptotic assay in lung sections from IL-13 treated mice which were treated with BAIC. As shown in Figure 7A, BAIC treatment reduced the IL-13 mediated increase in 13-S-HODE levels in lungs. This BAIC mediated reduction in 13-S-HODE levels was associated with the restoration of mitochondrial function which is demonstrated by an increase in complex I activity, cytochrome c oxidase activity in lung mitochondria and reduction in cytochrome c in lung cytosol (Fig. 7B–D). In addition, BAIC treatment reduced the caspase 3 activity and apoptosis of bronchial epithelia induced with IL-13 administration (Fig. 7E–F).
Earlier it was believed that airway inflammation plays the dominant role in asthma pathogenesis and airway epithelial injury was believed to be the downstream product of airway immune cell infiltration. Thus, therapeutic strategies were focused on reducing airway inflammation. However, recent reports including ours suggest that mitochondrial dysfunction and epithelial injury are crucial in allergic airway inflammatory diseases, such as asthma –. In addition, it has been demonstrated that epithelia may influence the immune status of the lung. It has also been strongly suggested that different therapeutic approaches can be devised by focusing more on protecting vulnerable airways against allergen induced injury . In this study, we have evaluated the potency of baicalein in reducing airway injury, mitochondrial dysfunction and alleviating the features of allergic asthma. We used allergic models and Th2 cytokine models to demonstrate the efficacy of baicalein in preventing airway injury. We found that baicalein ameliorates mitochondrial dysfunction, reduces airway injury and attenuates various features of airway inflammation, not only in the allergic model but also the Th2 cytokine models.
We found that baicalein reduced the perivascular and peribronchial infiltration of inflammatory cells, BAL fluid eosinophilia, eotaxin in lung and OVA specific IgE levels in sera. Earlier studies showed that baicalein reduced the production of eotaxin and stromal derived factor , , which are well known for their chemoattractant properties to recruit different types of leukocytes and eosinophil from the vasculature. Interestingly, baicalein inhibits TNF-α induced adhesion molecule expression in cultured human umbilical vein endothelial cells . In this study, baicalein treatment to allergic mice modulated the Th1/Th2 response by increasing IFN-γ, OVA specific IgG2a and decreasing IL-4 and IL-13. Further, baicalein treatment to OVA induced mice resulted in the reduction in TLR2 levels without affecting TLR-4 levels. A similar reduction of TLR-2 by baicalein has been reported in neurons . In addition, baicalein reduced the levels of 15-LOX metabolites such as 13-(S)-HODE and 9-(S)-HODE, which have been shown to be important in various features of inflammation such as chemotactic stimulation of leukocytes, and the activation and migration of lymphocytes . Consequently, the modulation of these different proinflammatory mediators by baicalein might explain the reduction of airway inflammation we observed in this study.
The reduction of 13-S-HODE and 9-S-HODE are interesting in asthmatic lungs since these metabolites are produced in large quantities by reticulocytes during the process of mitochondrial degeneration. Evidently, baicalein treatment is associated with the restoration of mitochondrial functions with increase in the activities of cytochrome c oxidase and complex I, and mitochondrial ultrastructural changes in asthmatic bronchial epithelia. Therefore, the reduction of mitochondrial dysfunction and restoration of ultra structural changes by baicalein could either be due to 15-LOX inhibition, or by indirect mechanisms such as the reduction of IL-4, IL-13 and lipid peroxidation. However, since baicalein is a nonspecific 12/15-LOX inhibitor, the observed effects of baicalein may not be due to 15-LOX inhibition alone. We have also found that baicalein treatment reduced the levels of secretory phospholipase A2 (data not shown), which is known to be a proinflammatory mediator in asthma pathogenesis . Whether this is a direct or indirect effect remains to be studied later.
Mitochondrial damage is commonly associated with epithelial injury in respiratory diseases . We found that baicalein reduced DNA fragmentation in bronchial epithelial cells and oxidative DNA damage. The anti-apoptotic effect of baicalein in OVA induced asthma model is interesting. It is known that baicalein causes apoptosis in various tumor cells –. In contrast, anti-apoptotic effects of baicalein have been demonstrated on normal cells under various stress conditions –. It is well known that cancer cells evade mitochondrial apoptotic mechanisms through depletion of mitochondria and shifting to a non-mitochondrial metabolism (Warburg effect). We speculate that this apparent anomaly may relate to such differences. However, further investigations are required to determine the effects of baicalein on primary lung epithelial cells.
Epithelial injury is one of the primary pathogenic mechanisms in asthma, since it initiates airway remodeling by inducing various growth factors such as TGF-β1. It has been shown that baicalein has anti-fibrotic properties in in vitro studies . In this study, baicalein had reduced the expression of TGF-β1 along with the reduction of collagen deposition in sub-epithelial regions. This is likely related to the inhibition of epithelial injury and pro-survival effects discussed above. Interestingly, baicalein treatment also reduced goblet cell metaplasia, which is an important aspect of other obstructive airway diseases like chronic bronchitis (Fig. 2). The mechanism of this is unclear, but appears to be a direct effect since baicalein pretreatment to IL-13 induced human bronchial epithelia reduced Muc5Ac levels in an in vitro study (Muc5Ac levels in pg/25 µg protein were 6.2±0.4, 11.5±1.3, 11.6±7.2, 6.7±1.6, 5.7±1.9 for uninduced, IL-13 induced with vehicle treated, and IL-13 induced and pretreated with 7.5 µM, 15 µM and 30 µM baicalein, respectively). 15-LOX has been previously implicated in goblet cell metaplasia –. Since baicalein has a broad spectrum of biological activities, the exact mechanism underlying its anti-asthma activities in this study are not clear. However, the inhibition of various proinflammatory mediators such as IL-4, IL-13, TGF-β1, 15-LOX, and reduction of 15-LOX metabolites such as 13-(S)-HODE and 9-(S)-HODE, are likely to lead to reduction of bronchial epithelial injury and consequent airway remodeling could be possible mechanisms by which baicalein reduces asthma features.
In summary, baicalein treatment to either allergic or Th2 cytokine induced mice reduces airway epithelial injury, ameliorates mitochondrial dysfunction, and various features of airway inflammation, in a mouse models and this could have an important implication in developing therapeutic strategies towards airway injury in asthma.
This animal study was performed in strict accordance with the guidelines provided by Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA). All animals (8–10 weeks old male BALB/c mice were obtained from National Institute of Nutrition, Hyderabad, India or Central Drug Research Institute, Lucknow and maintained in CSIR-Institute of Genomics and Integrative Biology, Delhi) utilized in this study were under protocols approved by Institutional Animal Ethics Committee of CSIR-Institute of Genomics and Integrative Biology, Delhi, India. All the surgical procedures were performed under sodium pentobarbital anesthesia and maximum efforts were taken for minimum suffering of animals.
There were two experimental models: a) OVA model and b) Th2 cytokine models. In OVA model, there were two sets of experiments: 1) Dose titration experiments in which there were 6 groups of mice (n=5–6 in each): SHAM/PBS/VEH (normal controls, VEH-vehicle), OVA/OVA/VEH (OVA controls, OVA, chicken egg ovalbumin, Grade V, Sigma) and OVA/OVA/BAIC 0.1, 1, and 10 (0.1 mg/kg, 1 mg/kg, and 10 mg/kg baicalein, respectively, Cayman); and 2) In verification experiments, there were two models: a) preventive model and b) therapeutic model. In preventive model, there were 3 groups (n=6 in each): SHAM/PBS/VEH, OVA/OVA/VEH and OVA/OVA/BAIC (baicalein, 10 mg/kg). In therapeutic model, there were 3 groups (n=6 in each): SHAM/PBS/VEH, OVA/OVA/VEH and OVA/OVA/BAIC 6 days (baicalein, 10 mg/kg). In both models, mice were sensitized on days 0, 7, and 14 with 50 µg OVA adsorbed in 4 mg alum or 4 mg alum alone and were challenged from Day 21 to Day 32 with 3% OVA or PBS consecutively as described earlier . Baicalein was dissolved in 5–10% dimethyl sulfoxide, vehicle. BAIC or VEH was administered intraperitoneally (i.p.) from day 21 to 32 twice a day in 100 µl volume per dose in preventive model and similar dose was given from day 27 to 32 in therapeutic model (Figure 1A). It is to be noted that other studies have used very high doses of baicalein (up to 520 mg/kg oral) without having any adverse effects , . We have used two different treatment durations to demonstrate the preventive and therapeutic effects of baicalein. Importantly we have not observed any adverse effects such as inflammation, loss of weight etc. in these mice or in naïve mice which have been given similar doses of baicalein for the similar duration (data not shown).
In Th2 cytokines model, 3 µg (30 µl) carrier-free recombinant murine IL-13 or IL-4 (R&D Systems) in 1% BSA or 1% BSA alone was instilled into the nasal openings of each isoflurane-anesthetized mouse, twice a day for 2 days and mice were treated with BAIC or VEH intraperitoneally (i.p.) twice a day for two days (Figure 4A). AHR measurement and euthanasia were performed on Day 3.
Airway hyperresponsiveness (AHR) to methacholine (MCh) was determined on Day 33 by single chamber body plethysmography or invasive instrument as described earlier , , . Briefly, each mouse was taken into the Buxco single chamber, acclimatized for 5–10 minutes, baseline recordings were measured for 5 minutes. Then mice were challenged with PBS or different concentrations of MCh aerosol and signal were recorded with in-built software (Buxco) to determine the Penh values which are reliable in Balb/c mice . Then MCh PC200 [the partial concentration of methacholine which is required to double the baseline enhanced pause (Penh)] was calculated. To confirm the findings from non-invasive body plethysmography, respiratory mechanics were determined during mechanical ventilation (flexiVent system, Scireq, Canada) as previously described . Briefly, anesthetized mice were intubated after tracheostomy, ventilated with computer-controlled ventilator and airway resistance with different concentrations of MCh was estimated using the flexiVent system (Scireq) that integrates ventilator with the respiratory mechanics .
TEM with first generation bronchi was performed . Briefly, all lungs were similarly fixed using combined in situ whole body perfusion and immersion . Fixed lungs were dissected using a dissection microscope to select the first generation bronchi. Slices from these bronchi were further processed, stained and viewed with TEM. In other experiments, Hematoxylin & Eosin staining, Periodic acid staining and Masson trichrome staining were performed in another portion of lung to assess inflammatory changes, goblet cell metaplasia and sub-epithelial fibrosis, respectively. Airway mucin content and collagen deposition were determined by quantitative morphometry as described earlier ,  with little modifications.
Lung cytosols were used for ELISA of 9-(S)-HODE (Oxford Biomedical research) and 13-(S)-HODE (Assay Designs Inc.) as per the manufacturer’s instructions.
Lung tissue homogenates were used for sandwich ELISA (BD Biosciences for IL-4, IFN-γ and TGF-β1, R&D systems for IL-13 and eotaxin and USCN life Science for TLR-2 and TLR-4) and results were expressed in picograms and normalized by protein concentrations . OVA specific IgE & IgG2a were measured as described earlier .
8-isoprostane, a marker of lipid peroxidation, was measured in lung homogenates by competitive ELISA and results were expressed in pg/25 µg protein. 8-OHdG, a marker of oxidative DNA damage, was measured in BAL fluid supernatants by competitive ELISA and results were expressed in pg/100 µl BAL fluid supernatants.
Total cytochrome c oxidase activity in lung mitochondria, caspase 3 activity and cytochrome c levels in lung cytosols were performed . Complex I activity (MitoSciences, USA) and caspase 12 activity (Biovision, USA) were determined as per manufacturer’s instructions.
This was performed as described earlier  with commercial goat polyclonal antibodies for cytochrome c oxidase III and TGF-β1 (Santa Cruz Biotechnology, Inc.) as primary antibodies and HRP conjugated anti-goat IgG as a secondary antibody. Negative control experiments were performed by using either gamma globulin as isotype controls (Jackson Immunoresearch Laboratories, Inc.) or omission of primary antibodies.
TUNEL assay of apoptosis was performed on lung tissue sections using an in situ apoptosis detection kit (Dead End Calorimetric TUNEL system; Promega) as described earlier –. Bronchial epithelial cells per lung section were examined by experimentally blind investigators and the numbers of apoptotic cells are expressed as a percentage of the whole epithelial cell population (apoptotic index).
To determine the direct effect of baicalein on mucin expression, BEAS-2B cells, human bronchial epithelia, were pretreated with vehicle (DMSO) or different concentrations of baicalein (7.5 µM, 15 µM and 30 µM) 3 hrs before induction without or with 20 ng/ml IL-13 for 48 hrs. After 48 hrs of IL-13 induction, cells were harvested and the levels of Muc5ac ELISA were determined in cell lysates (USCN life Science, China).
Data are expressed as mean ± SEM. Unpaired student’s ‘t’ test and ANOVA with post-hoc correction were performed to calculate the statistical significance which was set at p≤0.05.
We would like to thank Dr.Vijay Pal Singh, Mr. Bijay Pattnaik, Mr. Younis Ahmad Butt, Mr. Manish Kumar, Ms. Lipsa Panda, and Mr. Shailendra Singh for their helps. We thank Dr. Colin Jamora for his critical review.
This work was supported by grants BSC 0116 and MLP 5502 from the Council of Scientific and Industrial Research, Government of India. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.